Zobrazeno 1 - 10
of 22
pro vyhledávání: '"Lars Wilkinson"'
Autor:
Shiro Tanaka, Ryo Kawasaki, Lars Wilkinson, Kazuya Fujihara, Hirohito Sone, Tatsumi Moriya, Jakob Langer, Tim Morton, Nicki Hoskins, Sachiko Tanaka-Mizuno, Chika Horikawa, Rei Aida, Atsushi Araki
Publikováno v:
BMJ Open Diabetes Research & Care, Vol 9, Iss 1 (2021)
Introduction Cost-effectiveness analyses are becoming increasingly important in Japan following the introduction of a health technology assessment scheme. The study objective was to develop an economic model to evaluate the cost-effectiveness of two
Externí odkaz:
https://doaj.org/article/889320b8058d494abe785a4dc80082f1
The impact of severe haemophilia and the presence of target joints on health-related quality-of-life
Autor:
Jamie O’Hara, Shaun Walsh, Charlotte Camp, Giuseppe Mazza, Liz Carroll, Christina Hoxer, Lars Wilkinson
Publikováno v:
Health and Quality of Life Outcomes, Vol 16, Iss 1, Pp 1-8 (2018)
Abstract Background Joint damage remains a major complication associated with haemophilia and is widely accepted as one of the most debilitating symptoms for persons with severe haemophilia. The aim of this study is to describe how complications of h
Externí odkaz:
https://doaj.org/article/1effbe44dc7744dca5c20a5dbb7279d6
Autor:
Jamie O’Hara, Shaun Walsh, Charlotte Camp, Giuseppe Mazza, Liz Carroll, Christina Hoxer, Lars Wilkinson
Publikováno v:
Health Economics Review, Vol 8, Iss 1, Pp 1-7 (2018)
Abstract Objectives Target joints are a common complication of severe haemophilia. While factor replacement therapy constitutes the majority of costs in haemophilia, the relationship between target joints and non drug-related direct costs (NDDCs) has
Externí odkaz:
https://doaj.org/article/fbb6f774065241ed9b7a5a5a118a97dc
Autor:
Jane F. Beck, Lars Wilkinson, Donald M. Bushnell, Meryl Brod, Michael Højby Rasmussen, Lise Højbjerre, Johan Erpur Adalsteinsson
Publikováno v:
PharmacoEconomics Open
Background This study’s purpose was to assess the minimal important difference (MID) for the Treatment-Related Impact Measure—Adult Growth Hormone Deficiency (TRIM–AGHD), a patient-reported outcome measure assessing growth hormone deficiency (G
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::f0341e579ba1a7f46d2e0b5ba589b3fa
https://doi.org/10.1007/s41669-018-0082-3
https://doi.org/10.1007/s41669-018-0082-3
Publikováno v:
Diabetes Therapy
Introduction Once-weekly semaglutide is a new glucagon-like peptide-1 (GLP-1) analogue administered at a 1.0 or 0.5 mg dose. As head-to-head trials assessing once-weekly semaglutide as an add-on to 1–2 oral anti-diabetic drugs (OADs) vs other GLP-1
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::ed520d8c5a82f47fc7ba3ab69f5ea852
https://doi.org/10.1007/s13300-018-0424-2
https://doi.org/10.1007/s13300-018-0424-2
Publikováno v:
Diabetes Therapy
Introduction Once-weekly semaglutide is a glucagon-like peptide-1 (GLP-1) analogue that is currently available as 1.0 mg and 0.5 mg dose for the treatment of type 2 diabetes (T2D). Currently, no head-to-head trial investigating once-weekly semaglutid
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::fca14a34f1c240415291106cb9e388fd
http://europepmc.org/articles/PMC5984931
http://europepmc.org/articles/PMC5984931
Autor:
Richard F Pollock, Pierre Johansen, Neeraj N. Iyer, Lars Wilkinson, Tam Dang-Tan, Barnaby Hunt
Publikováno v:
Diabetes Therapy
Introduction The National Health and Nutrition Examination Surveys show that many people with type 2 diabetes (T2D) in the USA fail to achieve recommended treatment targets. In the SUSTAIN 7 randomized controlled trial, once-weekly semaglutide (0.5 a
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::8e2ff8628a309e71d6fd20752e543adb
https://doi.org/10.1007/s13300-018-0402-8
https://doi.org/10.1007/s13300-018-0402-8
Autor:
Tim Morton, Shiro Tanaka, Sachiko Tanaka-Mizuno, Hirohito Sone, Chika Horikawa, Atsushi Araki, Jakob Langer, Nicki Hoskins, Tatsumi Moriya, Lars Wilkinson, Ryo Kawasaki, Rei Aida, Kazuya Fujihara
Publikováno v:
BMJ Open Diabetes Research & Care, Vol 9, Iss 1 (2021)
BMJ Open Diabetes Research & Care
BMJ Open Diabetes Research & Care
IntroductionCost-effectiveness analyses are becoming increasingly important in Japan following the introduction of a health technology assessment scheme. The study objective was to develop an economic model to evaluate the cost-effectiveness of two i
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::9d61eab069bae3d6dd8c2a4a865e1957
https://doi.org/10.1136/bmjdrc-2021-002177
https://doi.org/10.1136/bmjdrc-2021-002177
Autor:
Rohini Sharma, Hrvoje Vrazic, Eric Druyts, Steve Kanters, Evan Popoff, Sandra Lopes, Lars Wilkinson
Publikováno v:
BMJ Open
ObjectiveTo determine the comparative efficacy of once-weekly semaglutide relative to sodium-glucose cotransporter 2 inhibitors (SGLT-2is) licensed in Europe and North America among patients with type 2 diabetes (T2D) inadequately controlled with 1
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::bdff30a4baac2ed8ed70ed31497d3223
https://pubmed.ncbi.nlm.nih.gov/31340953
https://pubmed.ncbi.nlm.nih.gov/31340953
Autor:
Lars Wilkinson, Sandra Lopes, Hrvoje Vrazic, Evan Popoff, Steve Kanters, Rohini Sharma, Eric Druyts
Objective: Treatment intensification with additional anti-diabetic agents is recommended in type 2 diabetes (T2D) for patients inadequately controlled on metformin monotherapy. The present network meta-analysis (NMA) evaluated comparative efficacy an
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::856127112fa82f1b87daae6b032d2658
